ACADIA Pharmaceuticals Inc
NASDAQ:ACAD

Watchlist Manager
ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Watchlist
Price: 16.42 USD 1.48% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
ACADIA Pharmaceuticals Inc?
Write Note

Wall Street
Price Targets

ACAD Price Targets Summary
ACADIA Pharmaceuticals Inc

Wall Street analysts forecast ACAD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACAD is 25.61 USD with a low forecast of 11.11 USD and a high forecast of 40.95 USD.

Lowest
Price Target
11.11 USD
32% Downside
Average
Price Target
25.61 USD
56% Upside
Highest
Price Target
40.95 USD
149% Upside

ACAD Last Price Targets
ACADIA Pharmaceuticals Inc

The latest public price target was made on Aug 7, 2024 by Jeffrey Hung from Morgan Stanley , who expects ACAD stock to rise by 22% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Jeffrey Hung
Morgan Stanley
20 USD
Upside 22%
3 months ago
Aug 7, 2024
Acadia downgraded to Equal Weight from Overweight at Morgan Stanley
TheFly
Keith Tapper
BMO Capital
31 USD
Upside 89%
4 months ago
Jun 26, 2024
Acadia Pharmaceuticals initiated with an Outperform at BMO Capital
TheFly
Uy Ear
Mizuho Securities
21 USD
Upside 28%
6 months ago
May 9, 2024
Acadia Pharmaceuticals (ACAD) PT Lowered to $21 at Mizuho
StreetInsider
Andrew Fein
H.C. Wainwright
27 USD
Upside 64%
6 months ago
May 9, 2024
Acadia Pharmaceuticals price target lowered to $27 from $33 at H.C. Wainwright
TheFly
Joel Beatty
Robert W. Baird
28 USD
Upside 71%
6 months ago
May 9, 2024
Acadia Pharmaceuticals price target lowered to $28 from $31 at Baird
TheFly
Ashwani Verma
UBS
27 USD
Upside 64%
6 months ago
Apr 30, 2024
Acadia Pharmaceuticals (ACAD) PT Lowered to $27 at UBS
StreetInsider
Ashwani Verma
UBS
33 USD
Upside 101%
8 months ago
Mar 12, 2024
Acadia Pharmaceuticals (ACAD) Stock Selloff Is Over Done Says UBS, 'the level of sell-off is surprising to us'
StreetInsider
Jay Olson
Oppenheimer
19 USD
Upside 16%
8 months ago
Mar 12, 2024
Acadia Pharmaceuticals (ACAD) PT Lowered to $19 at Oppenheimer, 'We now expect ACAD to optimize FCF generation with Nuplazid'
StreetInsider
Ami Fadia
Needham
32 USD
Upside 95%
8 months ago
Mar 12, 2024
Acadia Pharmaceuticals (ACAD) PT Lowered to $32 at Needham Citing Ph 3 Miss In NSS
StreetInsider
Sumant Kulkami
Canaccord Genuity
33 USD
Upside 101%
8 months ago
Mar 12, 2024
Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Canaccord Genuity, 'would not be surprised if ACAD decides to not pursue a sNDA in NSS'
StreetInsider
Jason Butler
JMP Securities
39 USD
Upside 138%
8 months ago
Mar 12, 2024
Acadia Pharmaceuticals (ACAD) PT Lowered to $39 at JMP Securities
StreetInsider
Show More Price Targets
Show Less Price Targets
Jeffrey Hung
Morgan Stanley
Price Target 20 USD
Upside/Downside 22%
View Source
Keith Tapper
BMO Capital
Price Target 31 USD
Upside/Downside 89%
View Source
Uy Ear
Mizuho Securities
Price Target 21 USD
Upside/Downside 28%
View Source
Andrew Fein
H.C. Wainwright
Price Target 27 USD
Upside/Downside 64%
View Source
Joel Beatty
Robert W. Baird
Price Target 28 USD
Upside/Downside 71%
View Source
Ashwani Verma
UBS
Price Target 27 USD
Upside/Downside 64%
View Source
Ashwani Verma
UBS
Price Target 33 USD
Upside/Downside 101%
View Source
Jay Olson
Oppenheimer
Price Target 19 USD
Upside/Downside 16%
View Source
Ami Fadia
Needham
Price Target 32 USD
Upside/Downside 95%
View Source
Sumant Kulkami
Canaccord Genuity
Price Target 33 USD
Upside/Downside 101%
View Source
Jason Butler
JMP Securities
Price Target 39 USD
Upside/Downside 138%
View Source
Show More Price Targets
Show Less Price Targets
ACADIA Pharmaceuticals Inc Competitors:
Price Targets
LVTX
LAVA Therapeutics NV
368% Upside
ORY
Oryzon Genomics SA
296% Upside
688105
Nanjing Vazyme Biotech Co Ltd
7% Upside
NANO
Nanobiotix SA
252% Upside
ALGEN
Genoway SA
80% Upside
PROB
Probi AB
39% Downside
NBIX
Neurocrine Biosciences Inc
32% Upside
STRO
Sutro Biopharma Inc
376% Upside

Revenue
Forecast

Revenue Estimate
ACADIA Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for ACADIA Pharmaceuticals Inc's revenue is 204%. The projected CAGR for the next 3 years is 18%.

204%
Past Growth
18%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
ACADIA Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
ACADIA Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ACAD's stock price target?
Price Target
25.61 USD

According to Wall Street analysts, the average 1-year price target for ACAD is 25.61 USD with a low forecast of 11.11 USD and a high forecast of 40.95 USD.

What is ACADIA Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
18%

For the last 8 years the compound annual growth rate for ACADIA Pharmaceuticals Inc's revenue is 204%. The projected CAGR for the next 3 years is 18%.

Back to Top